Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07225439
What this trial is testing

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Paolo Caimi, MD 15
Large-scale testing (Phase 3)Ended earlyNCT02907177
What this trial is testing

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

Who this might be right for
Multiple Sclerosis
Actelion 136
Testing effectiveness (Phase 2)Ended earlyNCT06018129
What this trial is testing

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaNon-Hodgkin Lymphoma
Genmab 9
Not applicableStudy completedNCT05663853
What this trial is testing

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
LAPIX Therapeutics Inc. 137
Testing effectiveness (Phase 2)Active Not RecruitingNCT07388277
What this trial is testing

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Who this might be right for
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Marcela V. Maus, M.D.,Ph.D. 12
Early research (Phase 1)Looking for participantsNCT07668557
What this trial is testing

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
iCell Gene Therapeutics 18
Testing effectiveness (Phase 2)Looking for participantsNCT07032129
What this trial is testing

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma Progression+1 more
Essen Biotech 60
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)Active Not RecruitingNCT04984837
What this trial is testing

Study of Lacutamab in Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapse/Recurrence
The Lymphoma Academic Research Organisation 49
Early research (Phase 1)Looking for participantsNCT06941129
What this trial is testing

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErythematosusSystemic Sclerosis (SSc)Inflammatory Myopathy+3 more
Institute of Hematology & Blood Diseases Hospital, China 12
Early research (Phase 1)Study completedNCT02482532
What this trial is testing

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

Who this might be right for
Melanoma
Gary Doolittle 7
Testing effectiveness (Phase 2)WithdrawnNCT02578121
What this trial is testing

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Who this might be right for
Multiple Myeloma
University of Arkansas
Testing effectiveness (Phase 2)Ended earlyNCT02983097
What this trial is testing

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid Variant+2 more
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 34
Testing effectiveness (Phase 2)Looking for participantsNCT05934513
What this trial is testing

GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc. 95
Early research (Phase 1)Ended earlyNCT00516282
What this trial is testing

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

Who this might be right for
Brain and Central Nervous System Tumors
Northwestern University 14
Testing effectiveness (Phase 2)Study completedNCT00622388
What this trial is testing

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Who this might be right for
Lymphoma, Large-Cell, Diffuse
GlaxoSmithKline 81
Early research (Phase 1)Study completedNCT05548088
What this trial is testing

LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia
Peking University People's Hospital 11
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Ended earlyNCT04639024
What this trial is testing

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Myeloproliferative Neoplasm (MDS/MPN)
Gwynn Long, M.D. 3
Testing effectiveness (Phase 2)Looking for participantsNCT07049926
What this trial is testing

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 140
Next Page